125 related articles for article (PubMed ID: 30552990)
1. The RNA helicase DHX33 is required for cancer cell proliferation in human glioblastoma and confers resistance to PI3K/mTOR inhibition.
Wang H; Yu J; Wang X; Zhang Y
Cell Signal; 2019 Feb; 54():170-178. PubMed ID: 30552990
[TBL] [Abstract][Full Text] [Related]
2. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.
Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK
Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759
[TBL] [Abstract][Full Text] [Related]
3. P19ARF and RasV¹² offer opposing regulation of DHX33 translation to dictate tumor cell fate.
Zhang Y; Saporita AJ; Weber JD
Mol Cell Biol; 2013 Apr; 33(8):1594-607. PubMed ID: 23401854
[TBL] [Abstract][Full Text] [Related]
4. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
[TBL] [Abstract][Full Text] [Related]
5. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
[TBL] [Abstract][Full Text] [Related]
6. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
7. DHX33 promotes colon cancer development downstream of Wnt signaling.
Zhu Y; Du Y; Zhang Y
Gene; 2020 Apr; 735():144402. PubMed ID: 32004669
[TBL] [Abstract][Full Text] [Related]
8. PTP4A3 is a target for inhibition of cell proliferatin, migration and invasion through Akt/mTOR signaling pathway in glioblastoma under the regulation of miR-137.
Wang L; Liu J; Zhong Z; Gong X; Liu W; Shi L; Li X
Brain Res; 2016 Sep; 1646():441-450. PubMed ID: 27328425
[TBL] [Abstract][Full Text] [Related]
9. Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.
Wu S; Wang S; Gao F; Li L; Zheng S; Yung WKA; Koul D
Neuro Oncol; 2018 Jan; 20(1):78-91. PubMed ID: 29016926
[TBL] [Abstract][Full Text] [Related]
10. MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
Radoul M; Chaumeil MM; Eriksson P; Wang AS; Phillips JJ; Ronen SM
Mol Cancer Ther; 2016 May; 15(5):1113-22. PubMed ID: 26883274
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells.
Djuzenova CS; Fiedler V; Memmel S; Katzer A; Sisario D; Brosch PK; Göhrung A; Frister S; Zimmermann H; Flentje M; Sukhorukov VL
BMC Cancer; 2019 Apr; 19(1):299. PubMed ID: 30943918
[TBL] [Abstract][Full Text] [Related]
12. Novel Dual PI3K/mTOR Inhibitor, Apitolisib (GDC-0980), Inhibits Growth and Induces Apoptosis in Human Glioblastoma Cells.
Omeljaniuk WJ; Krętowski R; Ratajczak-Wrona W; Jabłońska E; Cechowska-Pasko M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768941
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
[TBL] [Abstract][Full Text] [Related]
14. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
15. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
16. Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors.
Yuan J; Zhang F; Hallahan D; Zhang Z; He L; Wu LG; You M; Yang Q
J Exp Clin Cancer Res; 2018 Aug; 37(1):181. PubMed ID: 30071868
[TBL] [Abstract][Full Text] [Related]
17. Ganoderic acid A holds promising cytotoxicity on human glioblastoma mediated by incurring apoptosis and autophagy and inactivating PI3K/AKT signaling pathway.
Cheng Y; Xie P
J Biochem Mol Toxicol; 2019 Nov; 33(11):e22392. PubMed ID: 31503386
[TBL] [Abstract][Full Text] [Related]
18. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
19. Role of DHX33 in c-Myc-induced cancers.
Fu J; Liu Y; Wang X; Yuan B; Zhang Y
Carcinogenesis; 2017 Jun; 38(6):649-660. PubMed ID: 28498893
[TBL] [Abstract][Full Text] [Related]
20. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.
Laks DR; Oses-Prieto JA; Alvarado AG; Nakashima J; Chand S; Azzam DB; Gholkar AA; Sperry J; Ludwig K; Condro MC; Nazarian S; Cardenas A; Shih MYS; Damoiseaux R; France B; Orozco N; Visnyei K; Crisman TJ; Gao F; Torres JZ; Coppola G; Burlingame AL; Kornblum HI
Neuro Oncol; 2018 May; 20(6):764-775. PubMed ID: 29136244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
